A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3
1,280
about 2.5 years
12+
73 sites in AL, AR, AZ +24
About this study
Researchers are testing whether lutikizumab, a new medication, is better than placebo for treating moderate to severe hidradenitis suppurativa (HS) in adults and adolescents. The trial will last about 917 days and involve around 1280 participants at sites worldwide. Participants will receive either lutikizumab or placebo through injections every week or every other week, with some receiving the medication for a longer period.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lutikizumab
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
monoclonal antibody
Primary: Number of Participants with Adverse Events (AEs)
Secondary: Change from Baseline in Dermatology Life Quality Index (DLQI) among participants ≥ 16 years of age at Baseline, Change from Baseline in HSIA Mobility Domain, Change from Baseline in HSSA, Change from Baseline in Hidradenitis Suppurativa Impact Assessment (HSIA), Change from Baseline in Hidradenitis Suppurativa Impact Assessment (HSIA) Emotional Domain, Change from Baseline in Hidradenitis Suppurativa Symptom Assessment (HSSA) Worst Drainage Score, Change from Baseline in number of Draining Fistulas Count among participants with at least 1 draining fistula at Baseline, Change from Baseline in the Patient's Global Assessment of HS-related Odor (smell), based on the HSSA Question 8